Diagnostics For All Set To Take The Field For Clinical Trials

Not-for-profit start-up Diagnostics for All is set to begin a field trial in Kenya in March to evaluate a postage stamp-sized disposable diagnostic device to assess liver function in AIDS and TB patients. But the company eschews the notion that it's a charitable endeavor. Rather, it has crafted a licensing deal and business model that anticipates leveraging its not-for-profit work into a sustainable commercial First World business.

With more than $10 million in funding from the Gates Foundation and other grant sources and a network of volunteer professionals to bolster its six-person staff, not-for-profit start-up Diagnostics for All (DFA) is set to begin a field trial in Kenya in March to evaluate its energy- and water-independent, postage stamp-sized diagnostic device to assess liver function in AIDS and tuberculosis patients. But the company, launched out of the Harvard University laboratory of George Whitesides, PhD, eschews the notion that it's a charitable endeavor. Rather, CEO Una Ryan, PhD, and Harvard have crafted a licensing deal and business model that anticipates leveraging its not-for-profit work in the developing world into a sustainable commercial First World business.

DFA is built around a Whitesides' technology for running clinical chemistries and immunoassays using a single-use disposable. The device is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Ellipsis Raises $45M To Expand AI Care Manager Across Health Systems

 
• By 

Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

Somnee AI-Powered Sleep Wearable Raises $10M Seed Round

 

The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.

More from Business

Somnee AI-Powered Sleep Wearable Raises $10M Seed Round

 

The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.

Intuitive Surgical Projects $165M Tariff Hit In 2025, Says Wait-And-See On Mitigation

 
• By 

Despite near-term cost pressures, Intuitive Surgical is expanding manufacturing and R&D in North America and Europe to meet demand for Ion, X and Xi systems.

Three Steps To Investor Heaven For Medtech Founders: Articulate, Explain, Clarify

 
• By 

Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.